Immune checkpoint inhibitors (ICIs) have shown great promise in restoring T cell function and reactivating anti-tumor immunity. The FDA approved ipilimumab in 2011 for advanced melanoma, leading to significant improvements in survival rates. Seven ICIs, including ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and cemiplimab, have been approved for various cancers. However, their efficacy remains suboptimal, prompting research into next-generation ICIs such as LAG3, TIM3, and TIGIT. These checkpoints play roles in immune regulation and tumor suppression. TIM3 is a negative regulator of anti-tumor immunity, with high expression in cancer tissues and TILs. It is associated with poor prognosis in several cancers. Anti-TIM3 antibodies are under clinical trials, showing promising results in preclinical studies. LAG3 is also a negative regulator, with elevated expression in TILs and Tregs. It is linked to T cell exhaustion and poor outcomes in cancer. Anti-LAG3 antibodies are being tested in clinical trials, with some showing good tolerability and preliminary efficacy. TIGIT is another checkpoint that inhibits T cell function and is expressed on Tregs and tumor cells. Anti-TIGIT antibodies are under clinical trials, with some showing favorable safety profiles. Clinical trials for these checkpoints are ongoing, with early results indicating potential for improved patient outcomes. These next-generation ICIs offer new opportunities for cancer immunotherapy, particularly for patients who do not respond to current therapies. Further research is needed to optimize dosing, identify biomarkers, and explore combination strategies to enhance their effectiveness.Immune checkpoint inhibitors (ICIs) have shown great promise in restoring T cell function and reactivating anti-tumor immunity. The FDA approved ipilimumab in 2011 for advanced melanoma, leading to significant improvements in survival rates. Seven ICIs, including ipilimumab, pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and cemiplimab, have been approved for various cancers. However, their efficacy remains suboptimal, prompting research into next-generation ICIs such as LAG3, TIM3, and TIGIT. These checkpoints play roles in immune regulation and tumor suppression. TIM3 is a negative regulator of anti-tumor immunity, with high expression in cancer tissues and TILs. It is associated with poor prognosis in several cancers. Anti-TIM3 antibodies are under clinical trials, showing promising results in preclinical studies. LAG3 is also a negative regulator, with elevated expression in TILs and Tregs. It is linked to T cell exhaustion and poor outcomes in cancer. Anti-LAG3 antibodies are being tested in clinical trials, with some showing good tolerability and preliminary efficacy. TIGIT is another checkpoint that inhibits T cell function and is expressed on Tregs and tumor cells. Anti-TIGIT antibodies are under clinical trials, with some showing favorable safety profiles. Clinical trials for these checkpoints are ongoing, with early results indicating potential for improved patient outcomes. These next-generation ICIs offer new opportunities for cancer immunotherapy, particularly for patients who do not respond to current therapies. Further research is needed to optimize dosing, identify biomarkers, and explore combination strategies to enhance their effectiveness.